For more Wegovy information, including details about its usage, safety, and administration, explore additional resources or consult your healthcare provider
Funding source (industry vs
Genetic Predispositions That May Influence Retatrutide Response Individual variations in GLP-1R, GIPR, and glucagon receptor genes are known to influence peptide sensitivity and metabolic regulation
Advice for Healthcare Professionals The MHRA Drug Safety Update provides the following key guidance for healthcare professionals: Semaglutide treatment may be very rarely associated with NAION, which can cause vision loss, typically in one eye NAION typically presents as sudden, painless vision loss described as blurring or cloudiness Privately prescribed semaglutide may not appear on a patients medical record if a patient presents with these symptoms, enquire about semaglutide use Patients reporting sudden loss of vision (including partial loss) should be urgently referred for specialist examination by an ophthalmologist Discontinue semaglutide treatment if NAION is confirmed Advise new patients, or existing patients during medication reviews, to urgently attend eye casualty or A&E if they experience sudden vision loss or rapidly worsening eyesight An alert advised healthcare professionals to be vigilant for further issues, including rare but serious side effects such as acute pancreatitis
_edited.jpg)
.png)
